TABLE 3.

Summary of findings of studies included for anti‐CASPR2 encephalitis

Author/Year	No. of patients	Mean/Median age	Sex ratio/% male	Clinical presentation	CSF Abnormality	MRI (abnormality, commonest areas)	EEG abnormality	Outcome (mRs 0–2)	Relapse
Yeo et al., 2018	2	63	2/0 (100)	Limbic encephalitis 2/2	None	2/2 (100), B/l MTL hyperintensity (FLAIR)	2/2 (100), Bitemporal Sharp waves	2/2 (100)	2/2 (100)
Kannoth et al., 2018	3	54	2/1 (33)	Seizures, pain, tremor, disorientation	2/2 (100), increased protein	½ (50), small vessel ischemic changes	2/2 (100), mild electric dysfunction	1/3 (33.33)	1/3 (33.3)
Sunwoo et al., 2015	5	37.8	3/2 (60)	Seizures 80%, Insomnia 40%, Neuropathy and pain 40%	2/4 (50), 2 pleocytosis, 1 increased protein	2/5 (40), meningeal enhancement, MTL	5/5 (100), slowing, epileptiform discharges	4/5 (80.0)	N/A

Data are expressed as proportion (%), unless otherwise specified. Age is expressed in years.

Abbreviations: B/l, Bilateral; CSF, Cerebrospinal fluid; EEG, Electroencephalogram; MRI, Magnetic Resonance Imaging; MTL, Medial Temporal Lobe; N/A, Not available.